(64 days)
Not Found
No
The device description and performance studies focus on the chemical properties and stability of a glucose control solution, with no mention of AI or ML.
No.
This device is an in vitro diagnostic control solution used to assess the performance of a blood glucose monitor, not to provide therapy or directly treat a disease.
Yes
Explanation: The device is explicitly stated as "for in vitro diagnostic use." It is a control solution used to assess the performance of a blood glucose monitor, which is a diagnostic device itself.
No
The device description clearly states it is a liquid control solution packaged in plastic bottles, indicating it is a physical product, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states: "For in vitro diagnostic use".
N/A
Intended Use / Indications for Use
The FDI Glucose Control for Aviva is intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of Accu-Cнeк Aviva Blood Glucose Monitor.
Product codes (comma separated list FDA assigned to the subject device)
75 JJX
Device Description
The FDI Glucose Control for Aviva consists of a viscosity-adjusted, aqueous liquid control solution containing a known quantity of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is non-hazardous and contains no human or animal derived materials.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professionals and in the home by people with diabetes mellitus
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Tests were performed to verify specific performance characteristics:
-
- Real Time Stability
-
- Open Vial Stability
-
- Test precision
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
510(k) Premarket Notification: FDI Glucose Control for Aviva Fujirebio Diagnostics, Inc. ·
APR 2 0 2011
.
5 510(k) Summary
| Introduction: | According to the requirements of 21 CFR 807.92, the
following information provides sufficient detail to
understand the basis for a determination of
substantial equivalence. | | |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|--|
| Submitter: | Fujirebio Diagnostics, Inc.
940 Crossroads Blvd
Seguin, TX 78155
(830) 372-1391 ex. 210
Establishment Registration Number: 1643621 | | |
| Contact Person: | Kent Pruett | | |
| Device Name: | FDI Glucose Control for Aviva | | |
| Common Name: | Single Analyte Control Solution, All Types (Assayed
and Unassayed) | | |
| Classification Name: | Quality Control Material (assayed and unassayed). | | |
| Classification: | Class I per 21 CFR 862.1660 | | |
| Product Code: | 75 JJX | | |
| Panel: | Chemistry | | |
| Predicate Devices: | Name: | ACCU-CHEK Aviva Control Level 1 | |
| | Manufacturer: | Roche Diagnostics | |
| | 510(k) No.: | K043474 | |
| Device Description: | The FDI Glucose Control for Aviva consists of a
viscosity-adjusted, aqueous liquid control solution
containing a known quantity of glucose. The product
is packaged in plastic dropper tipped bottles for easy
application of the control solutions to the test strips
and a red coloration to aid the user to visually confirm
application of the control. The product is non-
hazardous and contains no human or animal derived
materials. | | |
| Intended Use: | The FDI Glucose Control for Aviva is intended for in
vitro diagnostic use (i.e. for external use only) by
healthcare professionals and in the home by people | | |
1
510(k) Premarket Notification: FDI Glucose Control for Aviva Fujirebio Diagnostics, Inc.
with diabetes mellitus to assess the performance of Accu-Cнeк Aviva Blood Glucose Monitor.
Comparison to Predicate Devices:
| Characteristic/
| Aspect | Predicate Device No. 1 | New Product |
|---|---|---|
| Name | ACCU-CHEK Aviva Control Level 1 | FDI Glucose Control for Aviva |
| 510(k), Date | K043474 | |
| 04/27/2005 | ||
| Number of Levels | 1 | 1 |
| Analyte | Glucose | Glucose |
| Target Range (mg/dL) | 25 - 55(1) | 19 - 51(2) |
| Container | Plastic bottle with dropper-tip | Plastic bottle with dropper-tip |
| Fill Volume | 2.5 mL | 3.6 mL |
| Color | Red | Red |
| Matrix | Glucose, buffer, salts, non- | |
| reactive ingredients, | ||
| preservative, FD & C Blue #1 | Buffered aqueous solution of D- | |
| Glucose, a viscosity modifier, | ||
| preservatives, and other non- | ||
| reactive ingredients | ||
| Indications for Use | Checks that the meter and test | |
| strips are working properly to | ||
| give reliable results. | To check the performance of the | |
| ACCU-CHEK Aviva Blood Glucose | ||
| System. | ||
| Target Population | Professional and home use | Professional and home use |
(1)Derived from the control ranges assigned by the manufacturer.
on ESTATUS and the Sent of ranges assigned by the manufacturer.
(2)Based on a +/- 5% glucose concentration variability lot-to-lot and +/- 15 mg/dl range
, !
Performance Studies: characteristics:
Tests were performed to verify specific performance
-
- Real Time Stability
-
- Open Vial Stability
-
- Test precision
Conclusion:
Comparison of the performance characteristics, formulation and intended use support the claim of substantial equivalence.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
Fujirebio Diagnostics, Inc. c/o Kent Pruett Director of Quality and Regulatory Affairs 940 Crossroads Blvd. Seguin, TX 78155
APR 2 0 2011
Re: K110436 Trade Name: FDI Glucose Control Solution for Aviva Regulation Number: 21 CFR 862.1660 Regulation Name: single (specified) analyte controls (assayed and unassayed) Regulatory Class: Class I, reserved Product Codes: JJX Dated: February 8, 2011 Received: February 15, 2011
Dear Mr. Pruett:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting (1 wr 1), it may obedoged in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not I vactar agencier - comments on CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
Page 2 -
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
C.C.
Courtney Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
510(k) Premarket Notification: FDI Glucose Control for Aviva Fujirebio Diagnostics, Inc.
4 Indications for Use Statement
510(k) Number (if known): K110436
Device Name: FDI Glucose Control for Aviva
Indications for Use:
For in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performononals the Aviva Blood Glucose Monitor.
Prescription Use X (21 CFR Part 801 Subpart D) AND/OR
Over-The-Counter Use X (21 CFR Part 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign Off
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K110436